China Influenza Vaccine Industry Report 2014

March 20, 2014

DUBLIN, March 20, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/n8dfqv/china_influenza) has announced the
addition of the “China Influenza Vaccine Industry Report 2014″
[http://www.researchandmarkets.com/research/n8dfqv/china_influenza ] report to their

http://photos.prnewswire.com/prnh/20130307/600769 )

The China Influenza Vaccine Industry Report 2014 is a professional and in-depth study
on the current state of the influenza vaccine industry in China.

The report provides a basic overview of the industry including definitions,
classifications, inoculation, industry chain structure and development prospects.
Influenza vaccine manufacturing technology and processes are discussed looking at
equipment, process problems and technology. Production, demand, cost, price, production
value and gross margin statistics are also provided.

A key feature of the report is its focus on 16 industry players providing information
such as capacity production, cost, price, production value, profit margins and other
relevant data. Next the feasibility of a new 8 Million Pieces/year influenza vaccine
investment project is assessed. Finally the report offers overall research conclusions

With 154 tables and figures the report provides key statistics on the state of the
industry and is a valuable source of guidance and direction for companies and individuals
interested in the market.

Key Topics Covered:

Chapter One Influenza Vaccine Industry Overview

Chapter Two Influenza Vaccine Manufacturing Technology and Process

Chapter Three Influenza Vaccine Production Supply Sales Demand Market Status and

Chapter Four Influenza Vaccine Key Manufacturers

Chapter Five China 8Million Pieces/Year Influenza Vaccine Project Investment
Feasibility Analysis

Chapter Six Influenza Vaccine Industry Research Conclusions

Companies Mentioned:

        - Abbott (US)
        - Aleph Biomedical (Liaoning)
        - CCBIO (Jilin Changchun)
        - Changsheng (Jilin Changchun)
        - Crucell (Holland)
        - GSK (UK)
        - Hualan Bio (Henan)
        - Lanzhou Institute of Biological Products (Qinghai)
        - Neptunus Interlong (Shenzhen)
        - Novartis (Switzerland)
        - SIOBP (Shanghai)
        - Sanofi-pasteur (France)
        - Sinovac (Beijing)
        - Tasly&Jenner (Tianjin)
        - Tiantan Biological (Beijing)
        - Tianyuan Bio-pharma (Zhejiang)

For more information visit


Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net



SOURCE Research and Markets

Source: PR Newswire

comments powered by Disqus